Inclusion Criteria:

- Diagnosis of advanced and/or metastatic cancer (including lymphoma) for which no
treatment of higher priority exists

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Estimated life expectancy of more than 12 weeks

- Have discontinued all previous therapies for cancer for at least 30 days (6 weeks for
mitomycin-C or nitrosoureas) and recovered from acute effects of therapy

- Have discontinued radiotherapy more than one week before enrolling in the study and
have recovered from the acute affects of therapy

- Have adequate organ function

- Follow your doctor's directions and live close enough to the study site so you can
continue to go to the clinic for follow-up

- Are willing and able to swallow capsules and follow study procedures

- Have given written informed consent prior to any study-specific procedures

- Males and females with reproductive potential should use medically approved
contraceptive precautions during the study and for 6 months following the last dose
of study drug

- Females with child-bearing potential must have had a negative urine or serum
pregnancy test 7 days prior to the first dose of study drug

Exclusion Criteria:

- Have gastrointestinal diseases or prior surgery that may interfere with the
absorption of medication taken by mouth

- Females who are pregnant or lactating

- Symptomatic central nervous system malignancy or metastasis

- Known positive test results in human immunodeficiency virus (HIV), hepatitis B
surface antigen (HBSAg), or hepatitis C antibodies (HCAb)

- Liver cirrhoses or chronic hepatitis

- Acute or chronic leukemia

- Are currently receiving treatment with valproic acid (VPA) and it's derivatives, or
if you have a history of intolerance to VPA

- Known hypersensitivity to gemcitabine